Cytochrome P450 2C19 loss-of-function polymorphism is associated with an increased treatment-related mortality in patients undergoing allogeneic transplantation

Bone Marrow Transplantation

Volumn 40, Issue 7, 2007, Pages 659-664

  Elmaagacli, A H ^a   Koldehoff, M ^a   Steckel, N K ^a   Trenschel, R ^a   Ottinger, H ^a   Beelen, D W ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BILIRUBIN; BUSULFAN; CIPROFLOXACIN; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOCHROME P450 2C19; FLUCONAZOLE; FLUDARABINE; METHOTREXATE; METRONIDAZOLE; THIOTEPA; THYMOCYTE ANTIBODY; TREOSULFAN;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOTRANSPLANTATION; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DONOR; DRUG METABOLISM; DRUG RESPONSE; ENZYME POLYMORPHISM; FEMALE; GENE MUTATION; GENOTYPE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HUMAN; INCIDENCE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; NEPHROTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT CODING; PRIORITY JOURNAL; RELAPSE;

ADOLESCENT; ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; FEMALE; GENOTYPE; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROMES; NEUTROPHILS; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 34648843006     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705786     Document Type: Article

References (23)

1. Daly AK. Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam Clin Pharmacol 2003; 17: 27-41.
2. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P4502C19 genetic polymorphism. Clin Pharmacol Ther 2005; 77: 40.
3. Timm R, Kaiser R, Lotsch J, Heider U, Sezer O, Weisz K et al. Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P4502C19. Pharmacogenomics J 2005; 5: 365-373.
4. Griskevicius L, Yasar U, Sandberg M, Hidestrand M, Eliasson E, Tybring G et al. Bioactivation of cyclophosphamide: The role of polymorphic CYP2C enzymes. Eur J Clin Pharmacol 2003; 59: 103-109.
5. Ishida Y, Goto Y, Kondo T, Kurata M, Nishio K, Kawai S et al. Eradication rate of Helicobacter pylori according to genotypes of CYP2C19, IL-1B, and TNF-A. Int J Med Sci 2006; 3: 135-140.
6. Kawabata H, Habu Y, Tomioka H, Kutsumi H, Kabayashi N, Oyasu K et al. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. Aliment Pharmacol Ther 2003; 17: 259-265.
7. Miki I, Aoyama N, Sakai T, Shirasaka D, Wambura CM, Maekawa S et al. Impact of clarithromycin resistence and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. Eur J Gastroenterol Hepatol 2003; 15: 27-33.
8. Kropp S, Lichtinghagen R, Winterstein K, Schlimme J, Schneider U. Cytochrome p-450 2D6 and 2C19 polymorphisms and length of hospitalization in psychiatry. Clin Lab 2006; 52: 237-240.
9. Mikus G, Schöwel V, Drzewinska M, Rengelshausen J, Ding R, Riedel KD et al. Potent cytochrome P4502C19 genotype-related interaction between voriconazol and the cytochrome P4503A4 inhibitor ritonavir. Clin Pharmacol Therap 2006; 80: 126-135.
10. Hulot J-S, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C et al. Cytochrome P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108: 2244-2247.
11. Ottinger HD, Ferencik S, Beelen DW, Lindemann M, Peceny R, Elmaagacli AH et al. Hematopoietic stem cell transplantation: Contrasting the outcome of transplantations from HLA-identical siblings, partially HLA-mismatched unrelated donors. Blood 2003; 102: 1131.
12. Elmaagacli AH, Peceny R, Steckel N, Trenschel R, Grosse-Wilde H, Schaefer UW et al. Outcome of transplantation of highly purified peripheral blood CD34 + cells with T-cell add-back compared with unmanipulated bone marrow or peripheral, blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia. Blood 2003; 101: 446.
13. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE et al. Bone marrow transplantation. N Engl J Med 1975; 292: 895.
14. Maniatis T, Fritsch EF, Sambrook J. Molecular Cloning. A Laboratory Manual. Cold Spring Harbor Laboratory Press: Harbor, NY, USA, 1982.
15. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
16. Cox DR. Regression models and life-tables. J R Stat Soc 1972; 34: 187.
17. Luo H-R, Poland RE, Lin K-M, Wan YJY. Genetic polymorphism of cytochrom P4502C19 in Mexican Americans: A cross-ethnic comparative study. Clin Pharmacol Ther 2006; 80: 33-40.
18. Hailing J, Petersen MS, Damkier P, Nielsen F, Grandjean P, Weihe P et al. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population. Pharmacogenetics 2005.
19. Elmaagacli AH, Koldehoff M, Hindahl H,. Steckel NK, Trenschel R, Peceny R et al. Mutations in innate immune system NOD2/CARD 15 and TLR-4 (Thr399Ile) genes influence the risk for severe acute GVHD in patients who underwent an allogeneic transplantation. Transplantation 2006; 81: 247-254.
20. Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents: Pharmacokinetics, safety and efficacy. Drugs 2004; 64 1997-2000.
21. Ikeda Y, Umemura K, Kondo K, Sekiguchi K, Miyoshi S, Nakashima, M. Pharmacokinetics of voriconazole and cytochrome P4502C19 genetic status. Clin Pharmacol Ther 2004; 75: 587-588.
22. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005; 352: 2211-2221.
23. Andersson T, Flockhart DA, Goldstein DB, Goldstein DB, Huang SM, Kroetz DL et al. Drug-metabolizing enzymes: Evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther 2005; 78: 559-581.